Niimi K, Harding D R K, Parshot R, King A, Lun D J, Decottignies A, Niimi M, Lin S, Cannon R D, Goffeau A, Monk B C
Department of Oral Sciences, University of Otago, Dunedin, New Zealand.
Antimicrob Agents Chemother. 2004 Apr;48(4):1256-71. doi: 10.1128/AAC.48.4.1256-1271.2004.
Hyperexpression of the Saccharomyces cerevisiae multidrug ATP-binding cassette (ABC) transporter Pdr5p was driven by the pdr1-3 mutation in the Pdr1p transcriptional regulator in a strain (AD/PDR5(+)) with deletions of five other ABC-type multidrug efflux pumps. The strain had high-level fluconazole (FLC) resistance (MIC, 600 microg ml(-1)), and plasma membrane fractions showed oligomycin-sensitive ATPase activity up to fivefold higher than that shown by fractions from an isogenic PDR5-null mutant (FLC MIC, 0.94 microg ml(-1)). In vitro inhibition of the Pdr5p ATPase activity and chemosensitization of cells to FLC allowed the systematic screening of a 1.8-million-member designer D-octapeptide combinatorial library for surface-active Pdr5p antagonists with modest toxicity against yeast cells. Library deconvolution identified the 4-methoxy-2,3,6-trimethylbenzensulfonyl-substituted D-octapeptide KN20 as a potent Pdr5p ATPase inhibitor (concentration of drug causing 50% inhibition of enzyme activity [IC(50)], 4 microM) which chemosensitized AD/PDR5(+) to FLC, itraconazole, and ketoconazole. It also inhibited the ATPase activity of other ABC transporters, such as Candida albicans Cdr1p (IC(50), 30 microM) and Cdr2p (IC(50), 2 microM), and chemosensitized clinical isolates of pathogenic Candida species and S. cerevisiae strains that heterologously hyperexpressed either ABC-type multidrug efflux pumps, the C. albicans major facilitator superfamily-type drug transporter Ben(R)p, or the FLC drug target lanosterol 14 alpha-demethylase (Erg11p). Although KN20 also inhibited the S. cerevisiae plasma membrane proton pump Pma1p (IC(50), 1 microM), the peptide concentrations required for chemosensitization made yeast cells permeable to rhodamine 6G. KN20 therefore appears to indirectly chemosensitize cells to FLC by a nonlethal permeabilization of the fungal plasma membrane.
在一株缺失其他五种ABC型多药外排泵的菌株(AD/PDR5(+))中,酿酒酵母多药ATP结合盒(ABC)转运蛋白Pdr5p的过表达由Pdr1p转录调节因子中的pdr1 - 3突变驱动。该菌株具有高水平的氟康唑(FLC)抗性(MIC,600μg ml(-1)),并且质膜组分显示寡霉素敏感的ATP酶活性比同基因PDR5缺失突变体(FLC MIC,0.94μg ml(-1))的组分高五倍。体外抑制Pdr5p的ATP酶活性以及细胞对FLC的化学增敏作用使得能够系统筛选一个由180万个成员组成的设计型D - 八肽组合文库,以寻找对酵母细胞毒性适中的表面活性Pdr5p拮抗剂。文库反卷积鉴定出4 - 甲氧基 - 2,3,6 - 三甲基苯磺酰基取代的D - 八肽KN20是一种有效的Pdr5p ATP酶抑制剂(导致50%酶活性抑制的药物浓度[IC(50)],4μM),它使AD/PDR5(+)对FLC、伊曲康唑和酮康唑化学增敏。它还抑制其他ABC转运蛋白的ATP酶活性,如白色念珠菌Cdr1p(IC(50),30μM)和Cdr2p(IC(50),2μM),并使致病性念珠菌属的临床分离株和异源过表达ABC型多药外排泵、白色念珠菌主要易化子超家族型药物转运蛋白Ben(R)p或FLC药物靶标羊毛甾醇14α - 去甲基酶(Erg11p)的酿酒酵母菌株对药物化学增敏。尽管KN20也抑制酿酒酵母质膜质子泵Pma1p(IC(50),1μM),但化学增敏所需的肽浓度使酵母细胞对罗丹明6G具有通透性。因此,KN20似乎通过真菌质膜的非致死性通透化作用间接使细胞对FLC化学增敏。